Oral Symptom Intensity, Health-Related Quality of Life, and Correlative Salivary Cytokines in Adult Survivors of Hematopoietic Stem Cell Transplantation with Oral Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 7, 2010, Pages 948-956

  Fall Dickson, Jane M ^a   Mitchell, Sandra A ^b   Marden, Susan ^a   Ramsay, Edward S ^a   Guadagnini, Jean Pierre ^c   Wu, Tianxia ^d   St John, Lena ^a   Pavletic, Steven Z ^e  

^a NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

^b CLINICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Oral chronic graft versus host disease; Quality of life; Symptoms

Indexed keywords

CODEINE; CYTOKINE; FENTANYL; HYDROMORPHONE; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; METHADONE; MORPHINE; OXYCODONE; PARACETAMOL; PERCOCET; PREDNISONE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHEMA; FAMILY; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MALE; MOUTH DISEASE; MOUTH PAIN; MOUTH ULCER; PREVALENCE; QUALITY OF LIFE; SALIVA LEVEL; SOCIAL ASPECT; SYMPTOM; WELLBEING; XEROSTOMIA;

ADULT; CHRONIC DISEASE; CYTOKINES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; QUALITY OF LIFE; SALIVA; SALIVARY PROTEINS AND PEPTIDES; SURVIVORS; YOUNG ADULT;

EID: 77953579262     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.01.017     Document Type: Article

References (57)

1. Shlomchik W.D., Lee S.J., Couriel D., et al. Transplantation's greatest challenges: advances in chronic graft-versus-host-disease. Biol Blood Marrow Transplant 2007, 13:2-10.
2. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
3. Fraser C.J., Baker K.S. The management and outcome of chronic graft-versus-host disease. Br J Haematol 2007, 138:131-145.
4. Treister N.S., Cook E.F., Antin J., et al. Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008, 14:110-115.
5. Jacobsohn D.A., Chan G.W., Chen A.R. Current advances in the treatment of acute and chronic graft-versus-host disease. Blood Marrow Transplant Rev 2007, 17:4-15.
6. Teshima T., Reddy P., Liu C., et al. Impaired thymic negative selection causes autoimmune graft-versus-host disease. Blood 2003, 102:429-435.
7. Tivol E., Komorowski R., Drobyski W.R. Emergent autoimmunity in graft-versus-host disease. Blood 2005, 105:4885-4891.
8. She K., Gilman A.L., Aslanian S., et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:386-397.
9. + T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006, 107:2993-3001.
10. Chen X., Vodanovic-Jankovic S., Johnson B., et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007, 110:3804-3813.
11. Hess A.D. Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol Blood Marrow Transplant 2006, 12:13-21.
12. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004, 104:2187-2193.
13. + regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 2006, 16:150-159.
14. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005, 106:2903-2911.
15. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111:3276-3285.
16. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
17. Schultz K.R., Miklos D.B., Fowler D., et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, III. Biomarker Working Group Report. Biol Blood Marrow Transplant 2006, 12:126-137.
18. Baird G.S., Montine T.J. Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch Pathol Lab Med 2008, 132:232-238.
19. Bazzichi L., Rossi A., Massimetti G., et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007, 25:225-230.
20. Cronstein B.N. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp J Dis 2007, 65(Suppl 1):S11-S15.
21. Gu G.M., Martin M.D., Darveau R.P., et al. Oral and serum IL-6 levels in oral lichen planus patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 98:673-678.
22. Klimiuk P.A., Sierakowski S., Latosiewicz R., et al. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003, 62:472-475.
23. Klimiuk P.A., Sierakowski S., Latosiewicz R., et al. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1666-1672.
24. Shahrara S., Proudfoot A.E., Park C.C., et al. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol 2008, 180:3447-3456.
25. Szodoray P., Alex P., Jonsson M.V., et al. Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005, 117:168-176.
26. Lloid M.E. Oral medicine concerns of the BMT patient. Bone Marrow Transplantation: Administrative and Clinical Strategies 1995, Jones and Bartlett Publishers, Boston, 257. P.C. Buchsel (Ed.).
27. Schubert M.M., Sullivan K.M., Morton T.H., et al. Oral manifestations of chronic graft-versus-host disease. Arch Int Med 1984, 144:1591-1595.
28. Nagler R.M., Nagler A. The molecular basis of salivary gland involvement in graft-vs-host disease. J Dent Res 2004, 83:98-103.
29. Logan R.M., Stringer A.M., Bowen J.M., et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007, 33:448-460.
30. Mitchell S.A., Leidy N.K., Mooney K.H., et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease. Bone Marrow Transplant 2009, Original Article E Pub ahead of print. 10.1038/bmt.2009.238.
31. Fraser C.J., Smith B., Ness K., et al. Impact of cGVHD on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006, 108:2867-2873.
32. Jellema A.P., Slotman B.J., Doornaert P., et al. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:751-760.
33. Scrimger R., Kanji A., Parliament M., et al. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy. Am J Clin Oncol 2007, 30:271-277.
34. Parliament M.B., Scrimgert R.A., Anderson S.G., et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity modulated radiotherapy (IMRT) for head and neck cancer. Int J Radiat Oncol Biol Phys 2004, 58:663-673.
35. Garcia M.K., Chiang J.S., Cohen L., et al. Acupuncture for radiation-induced xerostomia in patients with cancer: A pilot study. Head and Neck 2009, 31:1360-1368.
36. Rodrigues N.A., Kilion L., Hickey G., et al. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. 2009;. Int J Rad Onc Biol Phys 2009, 75:1079-1083.
37. Imanguli M.M., Pavletic S.Z., Guadagnini J.-P., et al. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 101:175-183.
38. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
39. Schubert M.M., Williams B.E., Lloid M.E., et al. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 1992, 69:2469-2476.
40. Gaston-Johansson F. Measurement of pain: the psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices. J Pain Symptom Manage 1996, 12:172-181.
41. Gift A., Narsavage A. Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care 1998, 7:200-204.
42. Williamson A., Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005, 14:798-804.
43. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
44. Brucker P.S., Yost K., Cashy J., et al. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005, 28:192-211.
45. Overcash J., Entermann M., Parr J., et al. Validity and reliability of the FACT-G scale for use in the older person with cancer. Am J Clin Oncol 2001, 24:591-596.
46. Padilla G.V., Frank-Stromborg M. Instruments for Clinical Health Care Research. Boston: Jones & Bartlett. Single instruments for measuring quality of life 1997, 114-134. M.F. Stromborg, S.J. Olsen (Eds.).
47. SAS Institute Inc. SAS 9.1.3, Cary, NC: SAS Institute Inc., 2002.
48. Pavletic S.Z., Martin P., Lee S.L., et al. Measuring therapeutic response in chronic graft-versus host disease: National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft versus host disease, IV: response criteria working group report. Biol Blood Marrow Transplant 2006, 12:252-266.
49. Volgelsang G.B., Lee L., Bensen-Kennedy D.M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Ann Rev Med 2003, 54:29-52.
50. Mandel I.D. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc 1989, 119:298-304.
51. Fein A.M., Abraham E.M. Can we make sense out of cytokines? Cytokines in acute and chronic inflammation. Front Biosci 1997, 2:d12-d26.
52. Aggarawal B.B., Samanta A., Feldman M. TNF-a. Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense 2001, 413-434. Academic Press, London. J.J. Oppenheim, M. Feldman (Eds.).
53. Fattori E., Cappelletti M., Costa P., et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994, 180:1243-1250.
54. Matsuda T., Hirano T. IL-6. Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense 2001, 537-563. Academic Press, London. J.J. Oppenheim, M. Feldman (Eds.).
55. + cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009, 113:3620-3630.
56. Worel N., Biener D., Kalhs P., et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:619-626.
57. Baker K.S., Fraser C.J. Quality of life and recovery after graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:333-341.